PCDH8 Inhibits Glioma Cell Proliferation by Negatively Regulating the AKT/GSK3β/β-catenin Signaling Pathway

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Sep 21

PMID 28927088

Citations 15

Authors

Zhenkun Zong

Hui Pang

Rutong Yu

Yunqi Jiao

Affiliations

Soon will be listed here.

Abstract

Protocadherin-8 (PCDH8), a member of the protocadherin superfamily of proteins, is frequently lost in numerous types of cancer. However, the role that PCDH8 serves in human glioma, and the molecular mechanisms underlying this, remain unclear. Data from the present study demonstrated that the expression levels of PCDH8 mRNA and protein were significantly decreased in human glioma tissue compared with normal brain tissue. This suggested that PCDH8 is associated with the development of glioma. Thus, the role of PCDH8 in glioma cell proliferation was investigated by silencing and overexpressing PCDH8 in U251 glioma cells. Overexpression of PCDH8 significantly inhibited glioma cell proliferation, while silencing of PCDH8 using small interfering RNA promoted glioma cell proliferation. Restoration of PCDH8 decreased phosphorylated (p)-Rac-α serine/threonine-protein kinase (AKT) [Threonine (T)308/Serine (S)473] and p-glycogen synthase kinase-3β (p-GSK3β) (S9) protein expression, thereby reducing the level of β-catenin when compared with the control. By contrast, silencing of PCDH8 increased levels of p-AKT (T308/S473) and p-GSK3β (S9), thereby increasing the level of β-catenin. In conclusion, the results of the present study suggested that PCDH8 suppressed glioma cell proliferation, and that the loss of PCDH8 may stimulate the proto-oncogene Wnt/β-catenin signaling pathway and therefore promote glioma cell proliferation.

Citing Articles

Improving iPSC Differentiation Using a Nanodot Platform.

Chiew M, Wang E, Lan K, Lin Y, Hsueh Y, Tu Y ACS Appl Mater Interfaces. 2024; 16(28):36030-36046.

PMID: 38951110 PMC: 11261571. DOI: 10.1021/acsami.4c04451.

PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability.

Yang R, Yang N, Yin P, Xue Z, Sun F, Fan R Funct Integr Genomics. 2024; 24(2):35.

PMID: 38368303 PMC: 10874333. DOI: 10.1007/s10142-024-01312-3.

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response.

Siamoglou S, Boers R, Koromina M, Boers J, Tsironi A, Chatzilygeroudi T Hum Genomics. 2023; 17(1):37.

PMID: 37098643 PMC: 10127336. DOI: 10.1186/s40246-023-00483-7.

Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients.

Feldheim J, Wend D, Lauer M, Monoranu C, Glas M, Kleinschnitz C Int J Mol Sci. 2022; 23(15).

PMID: 35897674 PMC: 9330298. DOI: 10.3390/ijms23158101.

Protocadherin gamma C3: a new player in regulating vascular barrier function.

Kaupp V, Blecharz-Lang K, Dilling C, Meybohm P, Burek M Neural Regen Res. 2022; 18(1):68-73.

PMID: 35799511 PMC: 9241426. DOI: 10.4103/.

References

Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q . PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway. Oncol Rep. 2015; 34(2):747-54. DOI: 10.3892/or.2015.4056. View

Stassar M, Devitt G, BROSIUS M, Rinnab L, Prang J, Schradin T . Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer. 2001; 85(9):1372-82. PMC: 2375251. DOI: 10.1054/bjoc.2001.2074. View

Okazaki N, Takahashi N, Kojima S, Masuho Y, Koga H . Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis. 2002; 23(7):1139-48. DOI: 10.1093/carcin/23.7.1139. View

Sano K, Tanihara H, Heimark R, Obata S, Davidson M, John T . Protocadherins: a large family of cadherin-related molecules in central nervous system. EMBO J. 1993; 12(6):2249-56. PMC: 413453. DOI: 10.1002/j.1460-2075.1993.tb05878.x. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Ying J, Li H, Seng T, Langford C, Srivastava G, Tsao S . Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2005; 25(7):1070-80. DOI: 10.1038/sj.onc.1209154. View

Lin Y, Wang Y, Ma J, Li W . Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2015; 33:68. PMC: 4237820. DOI: 10.1186/s13046-014-0068-7. View

Zhang D, Zhao W, Liao X, Bi T, Li H, Che X . Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. Oncol Rep. 2012; 28(5):1785-91. DOI: 10.3892/or.2012.1997. View

Phillips G, Tanaka H, Frank M, Elste A, Fidler L, Benson D . Gamma-protocadherins are targeted to subsets of synapses and intracellular organelles in neurons. J Neurosci. 2003; 23(12):5096-104. PMC: 6741188. View

10.

Liu Y, Wu K, Huang J, Liu Y, Wang X, Meng Z . The PTEN/PI3K/Akt and Wnt/β-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation. Int J Oncol. 2014; 45(1):104-12. DOI: 10.3892/ijo.2014.2392. View

11.

Lin Y, Ma J, Luo X, Guan T, Li Z . Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer. J Int Med Res. 2013; 41(1):48-54. DOI: 10.1177/0300060513475571. View

12.

He D, Zeng Q, Ren G, Xiang T, Qian Y, Hu Q . Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev. 2012; 21(6):569-75. DOI: 10.1097/CEJ.0b013e328350b097. View

13.

Ge X, Wang X . Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol. 2010; 3:33. PMC: 2954871. DOI: 10.1186/1756-8722-3-33. View

14.

Waha A, Guntner S, Huang T, Yan P, Arslan B, Pietsch T . Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia. 2005; 7(3):193-9. PMC: 1501138. DOI: 10.1593/neo.04490. View

15.

Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M . A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol. 2010; 80(1):54-68. DOI: 10.1016/j.critrevonc.2010.09.001. View

16.

Kim S, Yasuda S, Tanaka H, Yamagata K, Kim H . Non-clustered protocadherin. Cell Adh Migr. 2010; 5(2):97-105. PMC: 3084973. DOI: 10.4161/cam.5.2.14374. View

17.

Meyer M . Malignant gliomas in adults. N Engl J Med. 2008; 359(17):1850. DOI: 10.1056/NEJMc086380. View

18.

Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F . Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res. 2006; 66(9):4617-26. DOI: 10.1158/0008-5472.CAN-05-4437. View

19.

Strehl S, Glatt K, Liu Q, Glatt H, Lalande M . Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics. 1998; 53(1):81-9. DOI: 10.1006/geno.1998.5467. View

20.

Yu J, Koujak S, Nagase S, Li C, Su T, Wang X . PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 2008; 27(34):4657-65. PMC: 3013056. DOI: 10.1038/onc.2008.101. View